New Staphylokinase Variant RGD-SAK for Thrombolysis and Antiplatelet Activity
Author Information
Author(s): Chen Hongshan, Mo Wei, Su Huabo, Zhang Yanling, Song Houyan
Primary Institution: The Key Laboratory of Molecular Medicine, Ministry of Education, Fudan University
Hypothesis
The clot lysis efficacy of staphylokinase (SAK) can be enhanced with direct active platelet binding ability while minimizing rethrombosis complications.
Conclusion
RGD-SAK may serve as a more effective thrombolytic agent with both platelet-targeted thrombolytic and antiplatelet aggregation activities compared to SAK.
Supporting Evidence
- RGD-SAK showed significantly higher platelet binding activity compared to SAK.
- RGD-SAK reduced the time required for 50% platelet-rich clot lysis compared to SAK.
- RGD-SAK inhibited ADP-induced platelet aggregation in a concentration-dependent manner.
Takeaway
Researchers created a new version of a blood clot-dissolving protein that sticks better to platelets and helps prevent new clots from forming.
Methodology
The study involved site-directed mutagenesis to create RGD-SAK, followed by expression, purification, and various in vitro assays to evaluate its properties.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website